🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥

Startup Showcase

Premium Content

Try our Valuation Calculator →

News on Medial

Biotech startup Mestastop raises $500K for cancer drug discovery and repurposing technology

IndianStartupNews

IndianStartupNews · 1y ago

Biotech startup Mestastop raises $500K for cancer drug discovery and repurposing technology

Indian biotech startup Mestastop Solutions has secured $500,000 in a pre-Series A funding round led by a consortium of 92 angel investors and Malpani Ventures. The funds will be used to further the company's cancer metastasis platform, which utilizes wet lab biology and predictive analytics for drug discovery and patient treatment. Mestastop aims to generate proof of concept data and progress drug repurposing efforts to delay metastasis. The round follows a previous angel round in which the company raised INR 2 crore.

Related News

Louisa AI, Mestastop raise early-stage funding

VCCircle

VCCircle · 1y ago

Louisa AI, Mestastop raise early-stage funding

Louisa AI, a software-as-a-service startup, has raised $5 million in seed funding to expand its capabilities in forming B2B partnerships. The funding round included investors such as Palm Drive VC, Evolution VC, Nucleus VC, Gaingels, Oxford University's investment arms, and angel investors. Louisa AI focuses on eliminating conflicts of interest and specializes in sales enablement and deal-making. Biotechnology startup Mestastop has also secured follow-on funding from Mumbai Angels. Mestastop is creating a platform for cancer metastasis using wet lab biology and analytics for drug discovery and patient treatment.

Biotech startup Exsure raises seed round led by Unicorn India Ventures

Entrackr

Entrackr · 7m ago

Biotech startup Exsure raises seed round led by Unicorn India Ventures

Biotech startup Exsure has raised Rs 3 crore in a seed round led by Unicorn India Ventures. The fresh funds will be used to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries, the company said in a press release. Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform that targets both cancer and cancer stem cells. With its cutting-edge technology, the company aims to minimize the toxic effects of chemotherapy and reduce the likelihood of cancer relapse, thereby improving the quality of life for cancer patients. Over the past 12 months, Exsure has initiated a non-clinical study in India in collaboration with a CRO and completed preclinical studies using its patented technology. The company has launched its first in-house manufactured products and gained collaborators and partners across India for its products and services. According to market research, the Indian biotechnology industry is expected to reach $150 billion by 2025 and has the potential to grow to $270–300 billion by 2030. The Bhubaneswar-based company reported fivefold growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, including Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent). Additionally, the company has been selected for the OIST Innovation Accelerator Program in Japan to support its business expansion and conduct clinical trials.

Sacrifices, trade-offs paved big drug win: Glenmark CEO

Livemint

Livemint · 1m ago

Sacrifices, trade-offs paved big drug win: Glenmark CEO

Glenmark Pharmaceuticals' outlicensing deal with AbbVie for a novel blood cancer drug marks a significant step for the company and the Indian pharmaceutical industry. CEO Glenn Saldanha highlights the resilience and sacrifices involved in the innovation process, which ultimately led to success. The partnership reflects a commitment to advancing drug discovery despite the challenges, setting a new course for Glenmark and exemplifying strategic collaboration in the pharmaceutical sector.

CellCentric Raises $120M for Multiple Myeloma Drug; Genentech Pays $105M Upfront in $2B Orionis Cancer Deal | DeepNewz VC

deepnewz

deepnewz · 3m ago

CellCentric Raises $120M for Multiple Myeloma Drug; Genentech Pays $105M Upfront in $2B Orionis Cancer Deal | DeepNewz VC

CellCentric has successfully raised $120 million to support the development of its multiple myeloma drug. In a related pharmaceutical deal, Orionis Biosciences has entered a strategic partnership with Genentech, focusing on the discovery and development of a new class of cancer medicines known as molecular glues. This partnership includes an upfront payment of $105 million from Genentech, with the potential for additional payments totaling up to $2 billion.

Freenome Raises $254M in Funding

Finsmes · 1y ago

Freenome Raises $254M in Funding

San Francisco-based biotech company Freenome has raised $254 million in funding from investors including Roche and the American Cancer Society's BrightEdge Ventures. Freenome aims to develop blood tests for early cancer detection using its multiomics platform, which incorporates computational biology and machine learning. The funds raised will be used to advance the development of single-cancer and tailored multi-cancer early detection tests. The company is also working on screening tools to detect minimal residual disease (MRD) in partnership with biopharmaceutical and diagnostic companies.

AcuraStem Secures $7M in Grant Funding

Finsmes · 1y ago

AcuraStem Secures $7M in Grant Funding

AcuraStem, a biotech company based in Pasadena, has received a $7M grant from the National Institutes of Health (NIH) and Department of Defense (DOD). This funding, along with a recent licensing agreement with Takeda valued at $580M, will allow AcuraStem to advance multiple programs towards clinical trials for neurodegenerative diseases. The company's expertise in disease modeling and ASO technology positions them to develop innovative treatments for conditions like sporadic ALS and FTD. Their research is supported by various organizations, including the Alzheimer's Drug Discovery Foundation and Muscular Dystrophy Association.

Vivodyne Raises $40 Million to Develop Vascularized Organoids and Organs-on-Chip with FDA and NIH Support | DeepNewz VC

deepnewz

deepnewz · 3m ago

Vivodyne Raises $40 Million to Develop Vascularized Organoids and Organs-on-Chip with FDA and NIH Support | DeepNewz VC

Vivodyne, a biotech startup, has raised $40 million to develop vascularized organoids and organs-on-chip, which are lab-grown systems that mimic human organ functions. This technology is gaining traction as the FDA and NIH shift away from traditional animal testing methods. By creating human-like organ models, Vivodyne aims to transform drug testing and research, offering a more ethical and potentially more accurate alternative to animal testing in the pharmaceutical industry.

Cognizant, Nvidia tap generative AI to boost drug discoveries

Economic Times

Economic Times · 1y ago

Cognizant, Nvidia tap generative AI to boost drug discoveries

Cognizant, a global IT services and consulting company, is utilizing generative AI (gen AI) technology in collaboration with Nvidia's BioNeMo platform to enhance drug discovery productivity and accelerate market reach in the health sciences sector. By leveraging gen AI, clinical researchers can analyze large datasets, predict drug compound interactions, and create new paths for drug development. This breakthrough technology has the potential to revolutionize the drug discovery process, making it faster and more accessible. Cognizant aims to provide clients with model-making services and pretrained models, simplifying the training and customization of enterprise models. They will establish an Nvidia AI Center of Excellence to further innovate with Nvidia technologies.

J&J hired thousands of data scientists. Will the strategy pay off?

Livemint

Livemint · 1y ago

J&J hired thousands of data scientists. Will the strategy pay off?

Johnson & Johnson (J&J) is making strides in AI for drug discovery, boasting a team of 6,000 data scientists and digital specialists. The company, ranked third in CB Insights' Pharma AI Readiness Index, utilizes its massive database, med. AI, to accelerate drug development by identifying patterns in real-world data. J&J has already used machine learning to design an experimental cancer drug scheduled for human testing in 2024. Collaborating with startups and external partnerships, the company is leveraging AI in diagnostics, precision medicine, and image analysis, demonstrating a commitment to integrating data science into its pharmaceutical research.

J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?

Livemint

Livemint · 1y ago

J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?

Pharmaceutical and medical device company Johnson & Johnson is heavily investing in data science and artificial intelligence (AI) to enhance its work. The company has hired 6,000 data scientists and digital specialists, spending hundreds of millions of dollars on projects like using AI algorithms for diagnostics and virtual reality goggles for surgical training. Their ultimate goal is to use AI for drug discovery, and they have already used machine learning to design an experimental cancer drug. Johnson & Johnson's data-science workers are tightly integrated into the company's strategic decisions and have access to a vast database of anonymized patient data and clinical-trial results.

Trackers

Active Indian VC’s

OG Capital Email

With a hands-on approach, OG Capital aims to invest in over 20 promising...

Accel Partners Email

Early and growth-stage investments in disruptive technology companies with...

Early-stage venture capital firm investing in technology startups in India. Focus on...

Access All Trackers

Startup Showcase Winners

June 2025

Helping your parents when you are miles away

The Pit Stop Your Cravings Deserve

The next generation E-commerce platform

Enter Ongoing Startup Showcase

Top Users

Trending News on Medial

Just Months After Promotion, Open ...

Microsoft locks down a building a ...

Gaming Ban Stumps Cricket: Virat ...

Download the medial app to read full posts, comements and news.